Clinical Trial Update: To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating equivalence in pharmacokinetics and noninferiority of efficacy for CT-P10 versus Rituxan in lymphoma (follicular).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Lymphoma

Drugs mentioned

• CT-P10 (rituximab biosimilar)
• Rituxan (rituximab)

Snippet

Sponsor: Celltrion | Conditions: Lymphoma, Follicular | Phase 3 | Status: COMPLETED | Results posted: 2020-01-29